At the news
? BEARISHIMPACT 6/10 8-K filed Mar 19, 2026 at 06:02 ET
SAB Biotherapeutics is conducting a public offering of 19.3 million shares of common stock and pre-funded warrants to purchase up to 2.8 million shares at $3.85 per share, with an option for underwriters to purchase up to an additional 3.3 million shares. The company expects to raise approximately $69.7 million in net proceeds (up to $81.7 million if the option is exercised), which will be used primarily to fund clinical development of its lead product candidate SAB-142 for type 1 diabetes.
- Offering includes 19,324,677 shares of common stock and pre-funded warrants for 2,753,246 shares at $3.85 per share
- Underwriters have a 30-day option to purchase up to 3,311,688 additional shares
- Expected net proceeds of $69.7 million ($81.7 million if option exercised), after underwriting discounts and expenses
- Proceeds will be used to fund development of SAB-142 through clinical trials, manufacturing, regulatory activities, and general corporate purposes
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access